Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

How Does It Compare to Other Genomic Tests?

The Oncotype DX® portfolio includes tests for breast, colon, and prostate cancer and have helped more than 1 million patients make more informed treatment choices.1 Oncotype DX Breast Recurrence Score® test delivers critical genomic information to help guide treatment decisions that no other genomic test or risk assessment method provides.2,3

 

Icon 1

Reason # 1: Why genomic testing? Why not genetic?

Genetic tests help people understand their risk for getting cancer. Genomic tests help guide people who have been diagnosed with cancer choose an appropriate treatment plan.

 

Icon 2

Reason #2: Only the Oncotype DX Breast Recurrence Score test has predictive and prognostic results you can count on for your early-stage invasive breast cancer patients4-7

Comparison of Multi-gene Breast Cancer Tests

*Predicts the benefit of adding chemotherapy to endocrine therapy. 
†Node-negative and postmenopausal, HR positive, HER2 negative breast cancer. 
‡Early-stage invasive HR positive, HER2 negative breast cancer.

 

Icon 3

Reason #3: Breast Recurrence Score test vs traditional assessment methods

The Breast Recurrence Score test provides strong and consistent information beyond traditional clinical and pathologic features in patient subgroups. Traditionally, breast cancer treatment was based only on clinical-pathologic factors, which provide risk estimates for a patient population. The Breast Recurrence Score test is both prognostic and predictive, providing individualized information about the estimated risk of distant recurrence and benefit of adjuvant chemotherapy that goes beyond traditional assessment menthods.4-7,27,28

 

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V 2.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed May 2, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

ASCO and ESMO are trademarks of the American Society of Clinical Oncology. AJCC is a trademark of the American College of Surgeons. NCCN, ASCO, ESMO, St. Gallen, NICE, AGO and AJCC do not endorse any product or therapy.

Icon doctor

Use our online physician portal

Order tests, access results, receive updates, and more in one place.
Sign up now